[CARLSBG] YoY Annualized Quarter Result on 30-Sep-2022 [#3]

Stock
[CARLSBG] CARLSBERG BREWERY MALAYSIA BHD
Announcement Date
11-Nov-2022
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2022
Quarter
30-Sep-2022 [#3]
Profit Trend
QoQ- -5.12%
YoY- 98.29%
Quarter Report
Latest QR
Upcoming QR
CARLSBG's Result
CARLSBG's Financial Summary
View:
Show?
Annualized Quarter Result
30/09/24 30/09/23 30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 CAGR
Revenue 2,385,570 2,240,488 2,399,614 1,640,660 1,749,952 2,243,553 1,942,257 3.48%
PBT 462,222 431,521 473,721 223,144 214,542 385,864 363,997 4.05%
Tax -114,338 -91,406 -123,832 -47,674 -46,013 -81,260 -75,224 7.22%
NP 347,884 340,114 349,889 175,469 168,529 304,604 288,773 3.14%
-
NP to SH 344,384 332,296 342,566 172,761 165,645 296,033 279,602 3.53%
-
Tax Rate 24.74% 21.18% 26.14% 21.36% 21.45% 21.06% 20.67% -
Total Cost 2,037,686 1,900,373 2,049,725 1,465,190 1,581,422 1,938,949 1,653,484 3.54%
-
Net Worth 262,935 217,081 149,816 149,816 140,644 140,644 165,103 8.05%
Dividend
30/09/24 30/09/23 30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 CAGR
Div 264,973 252,751 256,828 40,766 - 222,584 210,762 3.88%
Div Payout % 76.94% 76.06% 74.97% 23.60% - 75.19% 75.38% -
Equity
30/09/24 30/09/23 30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 CAGR
Net Worth 262,935 217,081 149,816 149,816 140,644 140,644 165,103 8.05%
NOSH 305,738 305,748 305,748 305,748 305,748 305,748 305,748 -0.00%
Ratio Analysis
30/09/24 30/09/23 30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 CAGR
NP Margin 14.58% 15.18% 14.58% 10.70% 9.63% 13.58% 14.87% -
ROE 130.98% 153.07% 228.66% 115.32% 117.78% 210.48% 169.35% -
Per Share
30/09/24 30/09/23 30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 CAGR
RPS 780.26 732.79 784.83 536.61 572.35 733.79 635.25 3.48%
EPS 112.64 108.68 112.04 56.51 54.17 96.83 91.45 3.53%
DPS 86.67 82.67 84.00 13.33 0.00 72.80 68.93 3.88%
NAPS 0.86 0.71 0.49 0.49 0.46 0.46 0.54 8.05%
Adjusted Per Share Value based on latest NOSH - 305,748
30/09/24 30/09/23 30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 CAGR
RPS 780.27 732.81 784.86 536.62 572.37 733.82 635.27 3.48%
EPS 112.64 108.69 112.05 56.51 54.18 96.83 91.45 3.53%
DPS 86.67 82.67 84.00 13.33 0.00 72.80 68.94 3.88%
NAPS 0.86 0.71 0.49 0.49 0.46 0.46 0.54 8.05%
Price Multiplier on Financial Quarter End Date
30/09/24 30/09/23 30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 CAGR
Date 30/09/24 29/09/23 30/09/22 30/09/21 30/09/20 30/09/19 28/09/18 -
Price 19.68 20.00 22.50 22.40 20.70 26.26 20.00 -
P/RPS 2.52 2.73 2.87 4.17 3.62 3.58 3.15 -3.64%
P/EPS 17.47 18.40 20.08 39.64 38.21 27.12 21.87 -3.67%
EY 5.72 5.43 4.98 2.52 2.62 3.69 4.57 3.80%
DY 4.40 4.13 3.73 0.60 0.00 2.77 3.45 4.13%
P/NAPS 22.88 28.17 45.92 45.71 45.00 57.09 37.04 -7.70%
Price Multiplier on Announcement Date
30/09/24 30/09/23 30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 CAGR
Date 08/11/24 01/11/23 11/11/22 12/11/21 12/11/20 26/11/19 30/11/18 -
Price 19.62 19.82 23.40 21.64 23.24 27.00 19.72 -
P/RPS 2.51 2.70 2.98 4.03 4.06 3.68 3.10 -3.45%
P/EPS 17.42 18.24 20.88 38.30 42.90 27.89 21.56 -3.48%
EY 5.74 5.48 4.79 2.61 2.33 3.59 4.64 3.60%
DY 4.42 4.17 3.59 0.62 0.00 2.70 3.50 3.96%
P/NAPS 22.81 27.92 47.76 44.16 50.52 58.70 36.52 -7.53%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment